Emergent BioSolutions Inc. (EBS) Stock Forecast
EBS analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 3 analysts
- Price target
- $11.00 average of analyst targets
- Upside to target
- +72.4% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.45
- 52-week range
- $4.45 – $13.90
EBS analyst ratings
3 analystsNumber of analysts at each rating.
EBS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EBS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.41 | −$0.37 | $1.06 | −136.9% | 2 |
| Current fiscal year (2026) | $0.36 | $0.36 | $0.36 | $1.53 | −76.5% | 2 |
| Next fiscal year (2027) | $1.05 | $1.05 | $1.05 | $0.36 | +191.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EBS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $123.2M | $118.0M | $128.6M | −46.7% | 3 |
| Current fiscal year (2026) | $657.1M | $645.0M | $666.4M | −11.6% | 3 |
| Next fiscal year (2027) | $703.3M | $596.7M | $810.0M | +7.0% | 2 |
EBS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EBS revenue: reported and forecast
EBS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.35 | $0.35 | $0.35 | −$0.41 | −$0.39 | −211.8% | 1 up · 0 down |
| Current fiscal year (2026) | $0.95 | $0.95 | $0.95 | $0.36 | $0.36 | −62.1% | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | $1.05 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EBS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EBS beat in 7 of 12.
What analysts expect from EBS
3 analysts cover Emergent BioSolutions; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.00, 72.4% above the latest close of $6.38. Analysts expect earnings of $0.36 per share for 2026, −76.5% from a year earlier. For 2027 the average estimate is $1.05 per share on revenue of $703.3 million. Emergent BioSolutions beat the EPS estimate in 7 of the last 12 quarters.
Related: EBS income statement, EBS key metrics, EBS chart. See the EBS stock overview for the latest quote and news.
EBS forecast FAQ
What is Emergent BioSolutions's price target?
The average analyst price target for Emergent BioSolutions is $11.00, 72.4% above the latest close of $6.38.
Is Emergent BioSolutions a buy, hold or sell?
Of 3 analysts covering Emergent BioSolutions, 2 rate it a strong buy, 0 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Emergent BioSolutions's EPS forecast?
Analysts forecast $0.36 per share for 2026 (range $0.36 to $0.36); for 2027 the estimate is $1.05.
What is Emergent BioSolutions's revenue forecast?
The average revenue estimate for 2026 is $657.1 million, growth of −11.6%; for 2027 it is $703.3 million.
When does Emergent BioSolutions report earnings?
Emergent BioSolutions is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $-0.45.
Does Emergent BioSolutions usually beat earnings estimates?
Emergent BioSolutions reported EPS at or above the analyst estimate in 7 of the last 12 quarters.